The Economic Data calendar for the week of the 2nd of May through the 6th of May is full of critical releases and events. Here is a snapshot of some of the headline numbers that we will be focused on.
Takeaway: Current Investing Ideas: DE, HBI, LAZ, MDRX, FL, NUS, JNK, TIF, WAB, ZBH, ZROZ, XLU, MCD, GIS, TLT
Below are our analysts’ new updates on our fifteen current high conviction long and short ideas. As a reminder, if nothing material has changed in the past week which would affect a particular idea, our analyst has noted this.
Please note that we removed CME Group (CME) from the long side and added Deere & Company (DE) to the short side of Investing Ideas. Industrials Sector head Jay Van Sciver will send out a full stock report on Deere & Company next week. We will send CEO Keith McCullough’s updated levels for each ticker in a separate email.
As we penned in a 4/21 research note titled, “Important Thoughts On Market Structure and Sentiment”:
“Since the late-September lows, the S&P 500 has held a reasonably tight positive 0.75 correlation with the Citi U.S. Economic Surprise Index, which itself has rallied hard off its early-February lows as U.S. economic data stabilized in rate-of-change terms and perpetuated a waning of recession fears.
Now, a topping process in the latter index appears to have gotten underway over the past two weeks, as most recently highlighted by big misses in this morning's Philly Fed and Chicago NAI surveys. While our process generally underweights survey data – particularly one-off regional surveys – in lieu of doing the actual rate-of-change calculus on relevant “C” + “I” + “G” + “NX” metrics, we reiterate our view that economic deterioration from here is itself the catalyst for the stock market to reverse course a meaningful manner.
Simply put, because macro consensus doesn’t have our economic outlook, we believe domestic economic data will start to miss by wide margin again as it did in the early part of this year. It’s also worth noting that economist consensus always has a natural upward-sloping bias to their growth estimates, which creates additional downside surprise risk to the extent we're right on where the data is headed over the next couple of quarters.”
Source: Bloomberg L.P.
With the preponderance of key high-frequency data showing sequentially deteriorating economic momentum over the past week and the equity market (SPX) experiencing its largest weekly decline since early-February, that appears to have been a prescient call – for now at least. As always, the confluence of time and price will determine the ultimate winners and losers from here. The key highlights were Wednesday’s MAR Pending Home Sales bomb, Thursday’s paltry Q1 GDP report and Friday’s MAR Consumer Spending data.
The slowdowns highlighted above were in the context of reports earlier in the week that showed New Home Sales and New Orders growth for both Durable Capital Goods all decelerating in MAR.
In the interest of our goal to objective report the data, there were a couple of good economic releases over the previous week – namely the preliminary Markit Services and Composite PMI readings for the month of April. That said, however, the trend of deceleration from the late-2014 highs remains firmly intact.
The good thing about each of our active Macro positions (i.e. TLT, ZROZ, XLU and JNK) is that each of them typically works on an absolute return basis when growth slows:
And as we penned in a 4/28 research note titled, “Finally, Some Differentiated Thoughts on Q1 GDP…”:
“Despite today's weak print, U.S. GDP growth is very unlikely to rebound here in Q2. Don't get caught up in residual seasonality hopium.
… All told, the confluence of steepening base effects (to cycle-highs I might add) amid the trending deterioration in economic momentum support our GIP Model forecast of a continued deceleration in the YoY growth rate of real GDP from +1.9% in 1Q16 to +1% in 2Q16E. The latter growth rate translates to +0.3% on a QoQ SAAR basis, which is up from our previous forecast of -0.5% (a lower base rate implies a smaller delta to get to the same numbers, all things being equal).
Assuming Q1 isn’t revised in any material way, our forecast for 1H16E is represents the slowest pace of domestic economic growth on a multi-quarter basis since 2H12. Any downside surprises from there will surely translate to renewed recession fears.”
Giddy up for continued #GrowthSlowing!
To view our analyst's original report on Allscripts click here.
It was announced last week that Centra Health selected Cerner for an Enterprise wide EHR and Population Health system across the inpatient, ambulatory and post-acute care settings. Driving the replacement decision was McKesson's sunset of their Horizon EHR, which was installed in 4 hospitals (641 beds). On the ambulatory side, we spoke with several facilities and confirmed that Cerner will be replacing Allscripts Professional EHR and Practice Management system for ~180 docs. This amounts to ~$1.1 million in lost revenue assuming $529 per doc per month.
We continue to view Allscripts (MDRX) as a share donor in the ambulatory market, driven by health system consolidation and implementation of integrated systems.
Allscripts is scheduled to report earnings after the close on 5/5. We like the short setup into the print given the run up in the stock since the February lows as we believe bookings and sales disappoint.
To view our analyst's original report on McDonald's click here.
On Monday, in a note to Real-Time Alerts subscribers, Hedgeye CEO Keith McCullough asked rhetorically, "What to buy?"
"On pull backs to the low-end of my immediate-term risk range, I'd be buying more:
1. Long-duration Bond Exposures (TLT, ZROZ, EDV, etc)
2. Low-Beta Big Cap Stocks With Safe Yields (MCD, GIS, NKE, etc.)
3. Gold (GLD)"
McDonald's (MCD) has all the style factors we like for these turbulent markets, which explains why it's up 27% since we added it to Investing Ideas in August.
Stick with it here.
To view our analyst's original report on Wabtec click here.
“The biggest piece of that is rail. Looks like it's going to be a tougher year for our customers in rail. They have a lot of locomotives idled and we think some of the orders on hand are going to get moved out to a later than this year.” – DeWalt, CAT Earnings Call 4/22/16
Without draining the Freight backlog, WAB would have missed estimates by a sizeable margin. The decline in WAB’s freight backlog corresponds to about ~90 million in revenue above orders (i.e. demand) in the quarter. At a mid-20s margin, that adds perhaps $22 million in operating income. That operating income is from orders received in a different demand environment, and will likely prove unsustainable. That is about 15% of earnings.
Another important aspect of the release is simply that sales growth is now negative for the first time since the financial crisis. Sales are still elevated due to the lagged impact of revenue recognition from orders received by both Wabtec and the company’s OEM customers. We have visibility into further declines across North American rail equipment deliveries – locomotive & railcar deliveries have not really budged yet – so it is just a matter of time, we think.
To view our analyst's original report on Hanesbrands click here.
This week Hanesbrands (HBI) announced another acquisition. The target is Australian underwear brand owner Pacific Brands. This is a big deal, both in size and importance. With a price tag of $800mm, it is bigger than the Maidenform and DBA Apparel acquisitions ($575mm and $530mm respectively). The company is paying a high 10x EV/EBITDA multiple for an asset at the peak of the economic cycle.
We'll be back with some more details on the acquisition and any impact to our short thesis resulting from our research process.
To view our analyst's original report on Nu Skin click here.
There was nothing in the 1Q16 numbers that would leave us pondering the SHORT thesis we have on Nu Skin (NUS). The company is still under investigation by the SEC, because of questionable business practices, but they were unable to provide an update on the progress at this point.
NUS reported 1Q16 results which beat the “guidance” provided by management and the consensus estimates that the Street was tracking to. NUS reported revenues of $471.8 million versus consensus estimates of $466.4 million, and EPS of $0.42 versus consensus of $0.37. In addition to the beat, they raised full-year guidance due to an improved outlook on exchange rates and, to a lesser extent, better than expected early results on LTO’s.
Management’s guidance for the full year is revenue of $2.16 to $2.20 billion; 2Q16 revenue is projected to be $560 to $580 million. Full year 2016 EPS is expected to be in the range of $2.65 to $2.85, excluding a $0.36 per share non-cash Japan customs charge, and 2Q16 EPS is expected to be $0.75 to $0.79.
Now, that all sounds good on the face for a NUS bull. But digging deeper the business clearly continues to deteriorate. In addition to VitaMeal sales declines, NUS Sales Leaders numbers declined as well. This is a major problem for them because as you can see below, as sales leader numbers have declined, we have also seen a massive decline in revenue per sales leader. This business is not as lucrative as it is painted to be, and people are starting to figure that out. To the extent that NUS continues to see sales leader declines their business will continue to deteriorate.
To view our analyst's original report on Zimmer Biomet click here.
After a busy week of earnings, our Healthcare analysts Tom Tobin and Andrew Freedman went on HedgeyeTV to provide a recap and key takeaways on Zimmer-Biomet (ZBH) and other high-conviction names like athenahealth (ATHN), MEDNAX (MD), and Hologic (HOLX).
Click here to access the associated slides.
To view our analyst's original report on Tiffany click here.
In their most recent analyst day, Tiffany (TIF) management was directly asked about productivity improvements with store remodels. The company could not clearly say there is improvement after the remodels are done. Meanwhile, management has plans for continued renovations/remodels and considers it a cost of doing business. But, if there hasn’t been a consistent sales lift we wonder if they are really necessary.
At the same time, it seems clear that management intends to sacrifice productivity in some store expansions (Japan, Vancouver) believing it will lead to additional leverage, but again without positive historical performance it seems that there is a high risk of 4 wall margin dilution.
Investing capital in assets which will produce same or lower productivity is a quick path to lower asset returns and a lower stock price.
To view our analyst's original report on Lazard click here. Below is an analyst from Financials analyst Jonathan Casteleyn.
Lazard (LAZ) released its 10Q filing this week with data that was much worse than estimated. In the company's earnings report, it just outlines its financial results and not volume data. New information in the filing always includes industry M&A volumes, and with both completed, we learned M&A volume is cascading down. Completed M&A deals for the industry fell -10% year-over-year, which is backward looking and explains the very soft results in 1Q. However, announced activity per the 10Q fell even further at -20%, which means that the forward backlog is starting to get eaten away.
Furthermore, Lazard has one of the largest industry exposures to European activity and with the June 23rd BREXIT vote on the docket, there is a dearth of current deal making until corporate boards understand whether Great Britain will remain an EU industrial member. Both the M&A business and the firm’s asset management business continue to operate near peak margins which means there will be plenty of downside compression as activity continues to dry up. The stock is still highly recommended by most analysts that cover the stock and we are one of the only firms with a cautious view on shares.
To view our analyst's original report on Foot Locker click here.
Foot Locker's (FL) SG&A rate stands at an all-time low 19% of sales, the lowest we have seen in mall based retail. From 2010 to 2014, FL saw growth with minimal investment in SG&A, as traffic was driven by increased allocations of Nike product rather than Foot Locker spending on ads and customer experience.
In 2015, FL continued to leverage SG&A on the reported P&L, however, much of this was driven by FX rates causing lower SG&A costs internationally and not real underlying expense management. Now the SG&A rate is at trough, real leverage is tough from here, and FX is going from tailwind to headwind. As the SG&A rate goes up and comp growth slows, FL earnings will be going nowhere but down.
No update on General Mills (GIS) but we continue to like the company as one of the best large cap names in the packaged food space.
The total percentage of successful long and short trading signals since the inception of Real-Time Alerts in August of 2008.
In this brief excerpt from The Macro Show, Hedgeye CEO Keith McCullough and Retail analyst Alec Richards respond to a subscriber’s question about whether companies like Amazon and Facebook can continue to prop up equity markets.
Takeaway: Exchange activity remains positive year-over-year to start 2Q and any market draw down historically benefits volume.
Weekly Activity Wrap Up
Cash equity volume held steady at 7.0 billion shares traded per day this week, keeping the 2Q16TD average daily volume (ADV) in line at 7.0 billion, +10% higher than the year ago period in 2Q15. The volume of futures traded through CME and ICE contracted week-over-week to 18.6 million contracts traded per day, but still pushed 2Q16TD ADV to 18.4 million, +4% higher year-over-year. Furthermore, CME's open interest currently tallies 110.0 million contracts, +20% higher than the 91.3 million pending at the end of 2015. This compares to ICE's OI growth of just +4% since the beginning of the year. Lastly, options volume came in at 15.5 million, lower week-over-week but consistent with the 2Q16TD ADV, which is +1% higher against 2Q15.
U.S. Cash Equity Detail
U.S. cash equities trading came in at 7.0 billion shares per day this week, keeping the 2Q16TD ADV at 7.0 billion. That marks +10% Y/Y growth. The market share battle for volume is mixed. The New York Stock Exchange/ICE is taking a 25% share of second-quarter volume, which is +81 bps higher Y/Y, while NASDAQ is taking a 17% share, -166 bps lower than one year ago.
U.S. Options Detail
U.S. options activity came in at a 15.5 million ADV this week, keeping the 2Q16TD average at 15.5 million, a +1% Y/Y expansion. In the market share battle amongst venues, NYSE/ICE is taking a 17% share of 2Q16TD volume. Although that 17% is +61 bps higher than NYSE's year-ago share, it has been trending downwards. Additionally, CBOE's 25% market share of 2Q16TD is down -242 bps Y/Y. Meanwhile, NASDAQ is doing well in 2Q16TD, taking a 23% share, +95 bps higher than one year ago. BATS has also been taking share from the competing exchanges, up to an 11% share from 10% a year ago. Finally, although ISE/Deutsche's share expanded through 1Q16, it has been falling recently; at 14%, its share is -119 bps lower than 2Q15.
U.S. Futures Detail
13.9 million futures contracts per day traded through CME Group this week, bringing the 2Q16TD ADV to 13.8 million, +3% higher Y/Y. Additionally, CME open interest, the most important beacon of forward activity, currently sits at 110.0 million CME contracts pending, good for +20% growth over the 91.3 million pending at the end of 4Q15, although a contraction from last week's +21%.
Contracts traded through ICE came in at 4.6 million per day this week, bringing the 2Q16TD ADV to 4.6 million, a +7% Y/Y expansion. ICE open interest this week tallied 65.9 million contracts, a +4% expansion versus the 63.7 million contracts open at the end of 4Q15, consistent with last week's +4%.
Monthly Historical View
Monthly activity levels give a broader perspective of exchange based trends. As volatility levels, measured by the VIX, MOVE, and FX Vol should rise to normal levels after the drastic compression this cycle, we expect all marketplaces to experience higher activity levels.
Please let us know of any questions,
Jonathan Casteleyn, CFA, CMT
Joshua Steiner, CFA
Get The Macro Show and the Early Look now for only $29.95/month – a savings of 57% – with the Hedgeye Student Discount! In addition to those daily macro insights, you'll receive exclusive content tailor-made to augment what you learn in the classroom. Must be a current college or university student to qualify.